| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/07/2013 | EP2621931A1 Tetracyclic indole derivatives for treating hepatitis c virus infection |
| 08/07/2013 | EP2621929A1 Novel acridine derivatives |
| 08/07/2013 | EP2621928A1 7-hydroxy-pyrazolo[1,5-a]pyrimidine compounds and their use as ccr2 receptor antagonists |
| 08/07/2013 | EP2621926A2 Pyrazolopyrimidine pde10 inhibitors |
| 08/07/2013 | EP2621925A1 Fused tricyclic inhibitors of mammalian target of rapamycin |
| 08/07/2013 | EP2621923A1 N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases |
| 08/07/2013 | EP2621920A1 Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals |
| 08/07/2013 | EP2621919A1 Phenylquinazoline derivatives |
| 08/07/2013 | EP2621918A1 Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors |
| 08/07/2013 | EP2621917A1 Crystalline oxalate salts of a diamide compound |
| 08/07/2013 | EP2621916A1 Benzazole derivatives as histamine h4 receptor ligands |
| 08/07/2013 | EP2621914A1 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| 08/07/2013 | EP2621913A1 Substituted benzimidazole and imidazopyridine compounds useful as cyp17 modulators |
| 08/07/2013 | EP2621906A1 Diazaridine derivatives for treating metal disorders |
| 08/07/2013 | EP2621904A2 Compounds as c-met kinase inhibitors |
| 08/07/2013 | EP2621903A1 N-heteroaryl compounds |
| 08/07/2013 | EP2621902A2 3-azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders |
| 08/07/2013 | EP2621901A1 Selective androgen receptor modulators |
| 08/07/2013 | EP2621899A2 Novel methylcyclohexane derivatives and uses thereof |
| 08/07/2013 | EP2621891A1 Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same |
| 08/07/2013 | EP2621588A2 Methods and compositions for disease treatment using inhalation |
| 08/07/2013 | EP2621530A2 Improved adjuvant system for vaccine administration |
| 08/07/2013 | EP2621521A2 Minimizing intestinal dysfunction |
| 08/07/2013 | EP2621503A1 Use of a food product comprising viscous fibres which has a beneficial effect on cognitive performance. |
| 08/07/2013 | EP2621502A2 Modulation of timp1 and timp2 expression |
| 08/07/2013 | EP2621501A1 Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases |
| 08/07/2013 | EP2621500A2 Therapeutic use of a tlr agonist and combination therapy |
| 08/07/2013 | EP2621499A2 Methods for the treatment of allergic diseases |
| 08/07/2013 | EP2621498A2 Combination treatment for dermatological conditions |
| 08/07/2013 | EP2621497A2 Combination treatment for rosacea |
| 08/07/2013 | EP2621495A1 Combination therapy for treating hcv infection |
| 08/07/2013 | EP2621494A1 Use of magnesium stearate in dry powder formulations for inhalation |
| 08/07/2013 | EP2621493A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
| 08/07/2013 | EP2621492A1 Treatment of symptoms associated with menopause |
| 08/07/2013 | EP2621491A1 2-pyridone antimicrobial compositions |
| 08/07/2013 | EP2621490A2 Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use |
| 08/07/2013 | EP2621489A1 Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| 08/07/2013 | EP2621488A1 Cationic dry powders |
| 08/07/2013 | EP2621487A2 Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
| 08/07/2013 | EP2621486A1 Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
| 08/07/2013 | EP2621485A2 Low dose pharmaceutical composition comprising zanamivir |
| 08/07/2013 | EP2621484A1 Monovalent metal cation dry powders for inhalation |
| 08/07/2013 | EP2621483A1 Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| 08/07/2013 | EP2621482A1 Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| 08/07/2013 | EP2621481A1 Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
| 08/07/2013 | EP2621477A1 Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| 08/07/2013 | EP2621475A1 Treatment of tinnitus and related auditory dysfunctions |
| 08/07/2013 | EP2621472A1 Dry processing of atazanavir |
| 08/07/2013 | EP2621471A2 Pharmaceutical composition comprising deferasirox |
| 08/07/2013 | EP2621420A1 Corneal treatment system and method |
| 08/07/2013 | EP2621291A1 Fat composition for programming immune response |
| 08/07/2013 | EP2621282A2 Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
| 08/07/2013 | EP2621278A1 Alpha-ketoamide derivatives useful endothelial lipase inhibitors |
| 08/07/2013 | EP2621275A1 Aryl-substituted imidazoles |
| 08/07/2013 | EP2621273A2 Polyphosphate and pyrophosphate derivative of saccharides |
| 08/07/2013 | EP2366396B1 Myocardial perfusion imaging using adenosine receptor agonists |
| 08/07/2013 | CN203107746U Aspirin dipyridamole slow-release structure |
| 08/07/2013 | CN203107745U Aspirin dipyridamole slow-release structure |
| 08/07/2013 | CN1515244B Protein-stable pharmacological active matter, its preparation and application method |
| 08/07/2013 | CN103238070A Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest |
| 08/07/2013 | CN103237810A Anti-angiogenesis therapy for the treatment of ovarian cancer |
| 08/07/2013 | CN103237803A Triazolopyridine compounds |
| 08/07/2013 | CN103237802A 2-(R2-thio)-10-3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof |
| 08/07/2013 | CN103237801A Quinoline or quinazoline derivatives with apoptosis inducing activity on cells |
| 08/07/2013 | CN103237800A Amide derivative and use thereof |
| 08/07/2013 | CN103237799A Heterocyclic derivates, preparation processes and medical uses thereof |
| 08/07/2013 | CN103237798A Substituted benzimidazole and imidazopyridine compounds used as CYP17 modulators |
| 08/07/2013 | CN103237797A Quinolin-4 (1h)-ketone derivatives as inhibitors of phosphatidylinositol 3-kinases |
| 08/07/2013 | CN103237795A Substituted oxadiazole compounds and their use as S1P1 agonists |
| 08/07/2013 | CN103237794A P2X4 receptor antagonist |
| 08/07/2013 | CN103237793A Pyrazole compound having therapeutic effect on multiple myeloma |
| 08/07/2013 | CN103237790A Novel methylcyclohexane derivatives and uses thereof |
| 08/07/2013 | CN103237788A Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 08/07/2013 | CN103237786A Novel esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them, and their use as inhibitors of the thioredoxin -thioredoxin reductase system |
| 08/07/2013 | CN103237558A Minimizing intestinal dysfunction |
| 08/07/2013 | CN103237552A Treating conditions associated with increased eotaxin with 25-hydroxyvitamin D3 |
| 08/07/2013 | CN103237551A Pharmaceutical formulation having neuroprotective activity |
| 08/07/2013 | CN103237550A Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration |
| 08/07/2013 | CN103237549A Methods for treatment of allergic diseases |
| 08/07/2013 | CN103237548A Use of A2B adenosine receptor antagonists for treating pulmonary hypertension |
| 08/07/2013 | CN103237547A Crystalline naloxol-eg conjugate |
| 08/07/2013 | CN103237546A Anti-viral azide-containing compounds |
| 08/07/2013 | CN103237545A Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl-or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain |
| 08/07/2013 | CN103237542A Liposomal formulation of dalcetrapib |
| 08/07/2013 | CN103237541A Transfusion preparation |
| 08/07/2013 | CN103237538A Inhibitor of attachment of periodontal-isease-inducing bacterium onto surfaces of teeth, oral biofilm formation inhibitor, and composition for oral applications |
| 08/07/2013 | CN103237458A Curcuminoid solid dispersion formulation |
| 08/07/2013 | CN103237450A Heteroaryls and uses thereof |
| 08/07/2013 | CN103237446A Clevidipine emulsion formulations containing antimicrobial agents |
| 08/07/2013 | CN103233055A Preparation method and application of oleanolic 28-O-beta-D-glucopyranoside |
| 08/07/2013 | CN103232930A Honeysuckle multi-function health preserving wine and preparation method thereof |
| 08/07/2013 | CN103232539A Antibodies to opgl |
| 08/07/2013 | CN103232520A Spirosteroid compounds and preparation method and medical application thereof |
| 08/07/2013 | CN103232518A New salicornia bigelovii torr nortriterpenoid saponin compound, preparation method and uses thereof |
| 08/07/2013 | CN103232509A Fluorouracil compound, and preparation method and application thereof |
| 08/07/2013 | CN103232490A Nucleoside compounds with HIV-1/HBV viral replication inhibition activity, preparation methods thereof, and antiviral applications thereof |
| 08/07/2013 | CN103232486A Vanadium oxide complex as well as preparation method and application thereof |
| 08/07/2013 | CN103232477A Cefotiam hydrochloride compound, and preparation method and pharmaceutical composition thereof |
| 08/07/2013 | CN103232476A Antibacterial compound |
| 08/07/2013 | CN103232454A Medicine for treating mental disease |